IDEAYA and Servier report positive phase 2/3 trial results for uveal melanoma
IDEAYA Biosciences Inc. (NASDAQ: IDYA) and Servier announced that their Phase 2/3 OptimUM-02 trial met its primary endpoint, showing statistically ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)